<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076682</url>
  </required_header>
  <id_info>
    <org_study_id>2107239-9</org_study_id>
    <nct_id>NCT05076682</nct_id>
  </id_info>
  <brief_title>Reverse Triple Negative Immune Resistant Breast Cancer</brief_title>
  <acronym>Renaissance</acronym>
  <official_title>Reverse Triple Negative Immune Resistant Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of&#xD;
      combined treatment (sodium cromoglicate or choline) with immune checkpoint inhibitor in mTNBC&#xD;
      (triple negative breast cancer) patients who progressed during previous immune checkpoint&#xD;
      inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of&#xD;
      combined treatment (sodium cromoglicate or choline) with immune checkpoint inhibitors in&#xD;
      metastatic TNBCï¼ˆtriple negative breast cancer) patients who progressed during or following&#xD;
      previous immune checkpoint inhibitors. The investigators have achieved a breakthrough in&#xD;
      FUTURE study with an ORR (objective response rate) reaching 52.6% in IM (immune-modulatory)&#xD;
      subtype TNBC patients. Despite this, there are still some IM subtype patients resistant to&#xD;
      immunotherapy. How to reverse immunotherapy resistance or how to increase the sensitivity of&#xD;
      immunotherapy efficacy, has become an urgent clinical problem to be solved. The preclinical&#xD;
      results of our center show that TMAO and choline play a potentially important role in&#xD;
      regulating tumor immune microenvironment. Oral choline can improve TMAO content in mouse&#xD;
      serum, play the role of activating anti-tumor immunity, improve immunotherapy efficacy.&#xD;
      Preclinical studies of our center also show that sodium cromoglicate can enhance anti-tumor&#xD;
      immune response by inhibiting the activation of mast cells, increase the infiltration and&#xD;
      function of cytotoxic CD8+ T cells, inhibit the growth of tumors in mice, and enhance the&#xD;
      efficacy of PD-1 inhibitors in mice. Based on preclinical studies, the investigators designed&#xD;
      this study to enroll mTNBC patients who have progressed during or following immunotherapy,&#xD;
      and to explore the efficacy of choline or sodium cromoglicate combined with immunotherapy at&#xD;
      a clinical level, providing new strategies of combined treatment for TNBC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline until disease progression or loss of clinical benefit],assessed up to 6 months</time_frame>
    <description>The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DOR)</measure>
    <time_frame>Baseline through end of study,assessed up to 6 months</time_frame>
    <description>Complete remission or partial remission or stable disease (according to RECIST1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>Randomization to death from any cause, through the end of study,assessed up to 6 months</time_frame>
    <description>time to progressive disease (according to RECIST1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to death from any cause, through the end of study,assessed up to 12 months</time_frame>
    <description>time to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>choline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>choline with anti-PD-1 and chemo ( exactly same regimen in previous treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium cromoglicate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sodium cromoglicate with anti-PD-1 and chemo ( exactly same regimen in previous treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>choline</intervention_name>
    <description>choline 300mg tid or 500mg bid, p.o</description>
    <arm_group_label>choline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor and chemo</intervention_name>
    <description>PD-1antibody SHR1210 200mg q2w chemo (same regimen in previous treatment)</description>
    <arm_group_label>choline</arm_group_label>
    <arm_group_label>sodium cromoglicate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Cromoglicate</intervention_name>
    <description>Sodium Cromoglicate 200mg qid, p.o</description>
    <arm_group_label>sodium cromoglicate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER,&#xD;
             and PR expression)&#xD;
&#xD;
          -  Radiologic/objective evidence of recurrence or disease progression after&#xD;
             immunotherapy(combined with targeted therapy or chemo ) for metastatic breast&#xD;
             cancer(MBC)&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, laboratory test results, obtained within&#xD;
             14 days prior to initiation of study treatment.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive measures as outlined for each specific&#xD;
             treatment arm&#xD;
&#xD;
          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1&#xD;
             (RECIST v1.1)&#xD;
&#xD;
          -  have the cognitive ability to understand the protocol and be willing to participate&#xD;
             and to be followed up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing CNS metastases&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  History of malignancy other than breast cancer within 5 years prior to screening, with&#xD;
             the exception of those with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic&#xD;
             surgery excluded) within 3 weeks prior to initiation of study treatment.&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during the study&#xD;
&#xD;
          -  History of allergies to the drug components of this trial&#xD;
&#xD;
          -  History of eosinophilosis or mastocytosis&#xD;
&#xD;
          -  Patients who have been using oral steroid hormones for a long time will need to stop&#xD;
             for 4 weeks if they have used them occasionally in the past&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan U</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhimin Shao, Professor</last_name>
    <phone>08664175590</phone>
    <phone_ext>88807</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghua Wang, Professor</last_name>
    <phone>08664175590</phone>
    <phone_ext>88807</phone_ext>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhonghua Wang, Professor</last_name>
      <phone>+8664175590</phone>
      <phone_ext>88807</phone_ext>
      <email>zhonghuawang95@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yin Liu, Doctor</last_name>
      <phone>+8664175590</phone>
      <phone_ext>88603</phone_ext>
      <email>liuyinfudan@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>TNBC</keyword>
  <keyword>Molecular Subtype</keyword>
  <keyword>Precision Treatment</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>choline</keyword>
  <keyword>sodium cromoglicate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromolyn Sodium</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

